Rona M Smith

Summary

Country: UK

Publications

  1. doi Update on the treatment of ANCA associated vasculitis
    Rona M Smith
    Addenbrooke s Hospital, Department of Renal Medicine, Box 57, Hills Road, Cambridge CB20QQ, United Kingdom Electronic address
    Presse Med 44:e241-9. 2015
  2. pmc The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
    Helena Marco
    Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK
    BMC Musculoskelet Disord 15:178. 2014
  3. pmc Progress in treatment of ANCA-associated vasculitis
    Rona M Smith
    Department of Renal Medicine, Addenbrooke s Hospital, Hills Road, Cambridge CB20QQ, UK
    Arthritis Res Ther 14:210. 2012
  4. pmc Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis
    Federico Alberici
    Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke s Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke s Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke s Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
    Rheumatology (Oxford) 54:1153-60. 2015
  5. doi Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series
    Darren M Roberts
    Vasculitis and Lupus Clinic, Box 57, Addenbrooke s Hospital, Hills Rd, Cambridge CB20QQ, UK School of Medicine, University of Queensland, Butterfield Street, Herston, Queensland 4006, Australia Electronic address
    J Autoimmun 57:24-9. 2015
  6. doi Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis
    Rona M Smith
    Addenbrooke s Hospital, Cambridge, UK
    Arthritis Rheum 64:3760-9. 2012
  7. doi Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease
    Darren M Roberts
    Vasculitis and Lupus Clinic, Box 57, Addenbrooke s Hospital, Hills Rd, Cambridge, CB20QQ, UK School of Medicine, University of Queensland, Butterfield Street, Herston, Queensland, 4006, Australia Electronic address
    J Autoimmun 57:60-5. 2015
  8. doi Biological therapy for lupus nephritis-tribulations and trials
    Rona M Smith
    Department of Renal Medicine, Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, UK
    Nat Rev Rheumatol 6:547-52. 2010

Collaborators

Detail Information

Publications8

  1. doi Update on the treatment of ANCA associated vasculitis
    Rona M Smith
    Addenbrooke s Hospital, Department of Renal Medicine, Box 57, Hills Road, Cambridge CB20QQ, United Kingdom Electronic address
    Presse Med 44:e241-9. 2015
    ..As in rare diseases, treatment advances in vasculitis depend on international collaborative research networks to both establish an evidence base for newer agents and develop recommendations for optimal patient management. ..
  2. pmc The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
    Helena Marco
    Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK
    BMC Musculoskelet Disord 15:178. 2014
    ..CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels. However, after rituximab some patients develop hypogammaglobulinaemia...
  3. pmc Progress in treatment of ANCA-associated vasculitis
    Rona M Smith
    Department of Renal Medicine, Addenbrooke s Hospital, Hills Road, Cambridge CB20QQ, UK
    Arthritis Res Ther 14:210. 2012
    ..As rare diseases, treatment advances in vasculitis depend on international collaborative research networks both to establish an evidence base for newer agents and to develop recommendations for patient management...
  4. pmc Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis
    Federico Alberici
    Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke s Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke s Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke s Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
    Rheumatology (Oxford) 54:1153-60. 2015
    ..The aim of this study was to explore the long-term outcomes of AAV patients treated with repeat-dose RTX maintenance therapy...
  5. doi Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series
    Darren M Roberts
    Vasculitis and Lupus Clinic, Box 57, Addenbrooke s Hospital, Hills Rd, Cambridge CB20QQ, UK School of Medicine, University of Queensland, Butterfield Street, Herston, Queensland 4006, Australia Electronic address
    J Autoimmun 57:24-9. 2015
    ..IgG replacement for sustained hypogammaglobulinemia with recurrent infections appeared to be useful in this series. The IgG replacement course is prolonged in most patients, but IgG recovery is reported. ..
  6. doi Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis
    Rona M Smith
    Addenbrooke s Hospital, Cambridge, UK
    Arthritis Rheum 64:3760-9. 2012
    ..However, further relapse is common, and maintenance strategies are required. The aim of this study was to reduce relapse rates using a fixed-interval rituximab re-treatment protocol...
  7. doi Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease
    Darren M Roberts
    Vasculitis and Lupus Clinic, Box 57, Addenbrooke s Hospital, Hills Rd, Cambridge, CB20QQ, UK School of Medicine, University of Queensland, Butterfield Street, Herston, Queensland, 4006, Australia Electronic address
    J Autoimmun 57:60-5. 2015
    ..Rituximab is associated with an increased risk of hypogammaglobulinemia but recovery of IgG level can occur. IgG monitoring may be useful for patients receiving rituximab...
  8. doi Biological therapy for lupus nephritis-tribulations and trials
    Rona M Smith
    Department of Renal Medicine, Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, UK
    Nat Rev Rheumatol 6:547-52. 2010
    ..The complexities of clinical trials in lupus nephritis have impeded the demonstration of the efficacy of new agents, but if these difficulties can be overcome, there is a real chance that outcomes in lupus nephritis will improve...